News
The Company’s recently initiated Phase 2b clinical trial will further evaluate isomyosamine as a treatment for chronic inflammation associated with muscle loss (frailty or sarcopenia ...
The Company’s recently initiated Phase 2b clinical trial will further evaluate isomyosamine as a treatment for chronic inflammation associated with muscle loss (frailty or sarcopenia) in patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback